Kevin Lind
About Kevin Lind
Kevin R. Lind was appointed to Avalo Therapeutics’ Board of Directors on September 16, 2025, effective October 1, 2025; he is an independent director and immediately joined the Audit Committee . Lind is a seasoned biotech executive and investor who previously served as President & CEO of Longboard Pharmaceuticals (through its $2.6B acquisition by H. Lundbeck in 2024) and EVP & CFO of Arena Pharmaceuticals (pre-2022 Pfizer acquisition); he holds a B.S. in Biological Sciences from Stanford and an MBA from UCLA Anderson . He will enter Avalo’s standard indemnification agreement and there are no related-party transactions or selection arrangements with him .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Longboard Pharmaceuticals | President & CEO; Board Member | 2020–Dec 2024 (acquired by H. Lundbeck A/S) | Led innovative drug development; secured FDA Breakthrough Therapy designation; guided company to $2.6B acquisition |
| Arena Pharmaceuticals | EVP & CFO | 2016–2020 | Led turnaround; executed spinout of Longboard; secured BD partnerships |
| TPG Special Situations Partners | Healthcare investing | 2009–2016 | Investment leadership in healthcare |
| TPG-Axon | Healthcare investing | 2006–2008 | Investment roles |
| Lehman Brothers | Healthcare investment banking | 1998–2002; 2004–2006 | Capital markets and advisory experience |
External Roles
| Organization | Role | Tenure/Status | Notes |
|---|---|---|---|
| Apnimed, Inc. | Chairman of the Board | Current | Sleep-related therapeutics; current chair role |
Board Governance
- Committee assignments: Audit Committee member effective October 1, 2025 .
- Independence: Board determined Lind meets Nasdaq 5605(a)(2) and Rule 10A‑3 independence requirements .
- Board structure and executive sessions: Avalo separates Chair/CEO since March 2025 and independent directors meet alone at least twice per year .
- Attendance: No attendance data disclosed yet for Lind given his appointment in October 2025 (skip).
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual cash retainer (non‑employee director) | $40,000 | Effective July 1, 2024; paid quarterly; no per‑meeting fees |
| Audit Committee member fee | $10,000 | Annual fee; Chair $20,000 |
| Expense reimbursement | Reasonable meeting expenses reimbursed | Policy applies to non‑employee directors |
| Cash→Option election | Allowed | Directors may elect to receive a portion of cash retainer in options using Black‑Scholes/binomial fair value methodology |
Performance Compensation
| Award Type | Shares/Terms | Vesting Schedule | Notes |
|---|---|---|---|
| Initial non‑qualified stock options (Kevin Lind appointment grant) | 40,200 options | Vest in three equal annual installments on the 1st, 2nd, and 3rd anniversary of Oct 1, 2025 | Exercise price = closing price on Oct 1, 2025; subject to continued service |
| Annual director stock option grant (policy) | 17,050 options per year | Vests in full on first anniversary of grant | Applies at each annual meeting; effective July 1, 2024 policy |
| 2024 one‑time annual meeting equity grant (policy context) | 34,100 total shares (mix of options/RSUs) | Vests in three equal annual installments on Mar 28, 2025/2026/2027 | One‑time transitional structure per July 1, 2024 amendment; not specific to Lind |
Performance metrics tied to director compensation (none disclosed; time‑based vesting only):
| Metric Category | Description |
|---|---|
| Financial/TSR/ESG metrics | None for director equity; awards are time‑based per policy |
Plan governance features (apply to equity awards under Avalo’s Equity Incentive Plan):
- No single‑trigger accelerated vesting upon change‑in‑control .
- Clawback applicability for incentive compensation; awards subject to recovery per listing rules/Dodd‑Frank .
- Repricing of options/SARs prohibited without stockholder approval .
- Options must be granted at or above fair market value .
Other Directorships & Interlocks
| Company | Role | Status | Notes |
|---|---|---|---|
| Apnimed, Inc. | Chairman | Current | External chair role; not a disclosed related‑party transaction with Avalo |
| Longboard Pharmaceuticals | President & CEO; Director | Past | Led until Dec 2024 acquisition by H. Lundbeck A/S |
| Arena Pharmaceuticals | EVP & CFO | Past | Finance leadership 2016–2020 |
- Network linkage: Avalo CEO Garry Neil previously served on Arena’s board until its 2022 acquisition by Pfizer; Lind served as Arena’s EVP & CFO (2016–2020). This is a historical affiliation, not a related‑party transaction and the Board affirmed Lind’s independence .
Expertise & Qualifications
- Capital markets and strategic execution: Raised over $1.1 billion in equity capital; executed spinouts and acquisitions (Arena and Longboard) .
- Drug development leadership: Drove novel indication strategy and achieved FDA Breakthrough Therapy designation at Longboard .
- Financial acumen: Audit Committee member; significant CFO background, consistent with financial literacy expectations .
- Education: B.S. Biological Sciences (Stanford); MBA (UCLA Anderson) .
Equity Ownership
| Holding | Amount | Status | Notes |
|---|---|---|---|
| Initial appointment option grant | 40,200 options | Unvested at grant; 3‑year annual vesting | Exercisable price = Oct 1, 2025 closing; service‑based vesting |
| Beneficial ownership (shares/% outstanding) | Not disclosed | N/A | Lind joined after the April 22, 2025 ownership table; no individual Form 4 data disclosed here |
| Hedging/pledging policy | Hedging/shorts discouraged | Applies to directors | Insider Trading Policy discourages hedging/short sales/options transactions |
Governance Assessment
- Board effectiveness: Lind adds capital markets, M&A, and development expertise; his appointment to the Audit Committee strengthens financial oversight .
- Independence and conflicts: Board affirmed independence; no related‑party transactions; standard indemnification agreement; immediate Audit Committee placement under Rule 10A‑3 is a positive governance signal .
- Pay structure alignment: Equity‑heavy director compensation, optional cash‑to‑options election, no per‑meeting fees, and clawback coverage align director incentives with long‑term stockholder value and governance best practices .
- Risk indicators: Plan prohibits option repricing; no single‑trigger CIC vesting; insider trading policy discourages hedging—collectively reduce governance risk; no red flags identified specific to Lind at appointment .
Overall signal: Independent Audit Committee appointment, equity‑aligned pay, and deep transaction experience support investor confidence; no disclosed conflicts or attendance issues at this stage .